Concepedia

Laetitia Pouzol

LP

Statistics

Publications

7

Citations

169

H-Index

7

Active since

2019

Affiliations

Idorsia (Switzerland)(Current)

Laetitia Pouzol is an author at Idorsia (Switzerland) specializing in pharmacology, medicine, and multiple sclerosis pharmacotherapy.

ORCID

Publications per year

2019–2023

7

Publications

7

Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT-1004-1239

Sylvia Richard‐Bildstein, Hamed Aissaoui, Julien Pothier et al. · Journal of Medicinal Chemistry · 2020 · 44 citations · Full text

, , +17

ACT‐1004‐1239, a first‐in‐class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases

Laetitia Pouzol, Nadège Baumlin, Anna Sassi et al. · The FASEB Journal · 2021 · 36 citations · Full text

, , +17

CXCR7 Antagonism Reduces Acute Lung Injury Pathogenesis

Laetitia Pouzol, Anna Sassi, Nadège Baumlin et al. · Frontiers in Pharmacology · 2021 · 26 citations · Full text

, , +17

Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis.

Laetitia Pouzol, Luca Piali, Claude C.A. Bernard et al. · PubMed · 2019 · 18 citations

, , +16

Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies

Emmanuel A. Meyer, Päivi Äänismaa, Eric A. Ertel et al. · Journal of Medicinal Chemistry · 2023 · 16 citations · Full text

, , +17

1–5 of 7